JP2021510723A5 - - Google Patents

Info

Publication number
JP2021510723A5
JP2021510723A5 JP2020540345A JP2020540345A JP2021510723A5 JP 2021510723 A5 JP2021510723 A5 JP 2021510723A5 JP 2020540345 A JP2020540345 A JP 2020540345A JP 2020540345 A JP2020540345 A JP 2020540345A JP 2021510723 A5 JP2021510723 A5 JP 2021510723A5
Authority
JP
Japan
Prior art keywords
powder
shell
composition according
container
composition
Prior art date
Application number
JP2020540345A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019145897A5 (https=
JP2021510723A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/050607 external-priority patent/WO2019145897A1/en
Publication of JP2021510723A publication Critical patent/JP2021510723A/ja
Publication of JPWO2019145897A5 publication Critical patent/JPWO2019145897A5/ja
Publication of JP2021510723A5 publication Critical patent/JP2021510723A5/ja
Pending legal-status Critical Current

Links

JP2020540345A 2018-01-26 2019-01-24 吸入型治療薬の高用量送達 Pending JP2021510723A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862622464P 2018-01-26 2018-01-26
US62/622,464 2018-01-26
PCT/IB2019/050607 WO2019145897A1 (en) 2018-01-26 2019-01-24 High dose delivery of inhaled therapeutics

Publications (3)

Publication Number Publication Date
JP2021510723A JP2021510723A (ja) 2021-04-30
JPWO2019145897A5 JPWO2019145897A5 (https=) 2022-01-19
JP2021510723A5 true JP2021510723A5 (https=) 2022-01-19

Family

ID=65635769

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020540345A Pending JP2021510723A (ja) 2018-01-26 2019-01-24 吸入型治療薬の高用量送達

Country Status (14)

Country Link
US (1) US20210069106A1 (https=)
EP (1) EP3743045A1 (https=)
JP (1) JP2021510723A (https=)
KR (1) KR20200115560A (https=)
CN (1) CN111526870A (https=)
AR (1) AR114308A1 (https=)
AU (2) AU2019212586C1 (https=)
BR (1) BR112020014793A2 (https=)
CA (1) CA3089439A1 (https=)
CL (1) CL2020001939A1 (https=)
IL (1) IL276241A (https=)
MX (1) MX2020007745A (https=)
RU (1) RU2020127882A (https=)
WO (1) WO2019145897A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12233177B2 (en) 2019-09-16 2025-02-25 Amgen Inc. Method for external sterilization of drug delivery device
LT4051708T (lt) 2019-10-28 2025-04-10 Medimmune Limited Užkrūčio liaukos stromos limfopoetiną (tslp) surišančių antikūnų sausų miltelių pavidalo vaisto formos ir jų panaudojimo būdai
CN119306869B (zh) * 2024-12-13 2025-05-16 万华化学集团股份有限公司 一种乙烯/α-烯烃共聚物及其制备方法、采用其的封装胶膜

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037303A1 (en) 2001-11-01 2003-05-08 Nektar Therapeutics Spray drying methods and compositions thereof
MXPA05007154A (es) 2002-12-30 2005-09-21 Nektar Therapeutics Atomizador prepeliculizacion.
KR20130066695A (ko) * 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
EP2076242B8 (en) * 2006-07-27 2013-02-20 Nektar Therapeutics Aerosolizable formulation comprising insulin for pulmonary delivery
TR200907236A2 (tr) * 2009-09-23 2011-04-21 Bi̇lgi̇ç Mahmut Tiotropyum kuru toz formülasyonunun blister ambalajda taşınması.
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
CN107596518B (zh) * 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
WO2014144364A1 (en) * 2013-03-15 2014-09-18 Children's Medical Center Corporation Gas-filled stabilized particles and methods of use
US20180303753A1 (en) * 2015-09-09 2018-10-25 Keith Try Ung Targeted delivery of spray-dried formulations to the lungs
AU2016320748B2 (en) * 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
PE20181307A1 (es) * 2016-01-19 2018-08-10 Novartis Ag Inhalador multidosis
WO2017132601A1 (en) * 2016-01-29 2017-08-03 Mannkind Corporation Dry powder inhaler

Similar Documents

Publication Publication Date Title
AU2025204271A1 (en) Microcrystalline diketopiperazine compositions and methods
JP6491658B2 (ja) 熱安定性乾燥粉末医薬組成物及び方法
CN106163598B (zh) 尼古丁粉末吸入器
AU2019282808B2 (en) Composition and method for inhalation
US6616914B2 (en) Method for pulmonary and oral delivery of pharmaceuticals
ES2880271T3 (es) Polvos pulmonares de ultra baja densidad
CA2838030A1 (en) Combination comprising umeclidinium and a corticosteroid
Kaur et al. Advanced aerosol delivery devices for potential cure of acute and chronic diseases
JP2021510723A5 (https=)
US20190321290A1 (en) Composition and method for inhalation
JP2025061049A (ja) 吸入可能な乾燥粉末
Carvalho et al. Dry powder inhalation for pulmonary delivery: recent advances and continuing challenges
UA119774C2 (uk) Комбінації формотеролу і будесоніду для лікування хронічної обструктивної хвороби легень (хохл)
JP2007520507A5 (https=)
US20250228779A1 (en) Method and composition for treating pulmonary fibrosis
IT202000005026A1 (it) Lattoferrina per uso inalatorio ad azione antivirale
RU2020127882A (ru) Доставка высоких доз ингаляционных терапевтических средств
SE527200C2 (sv) Inhalatoranordning samt kombinerade doser av formaterol och fluticason
JP2023524064A (ja) ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法
EP2931252A1 (en) Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
JPWO2019145897A5 (https=)
AU2022376952A1 (en) Methods and compositions for treating pulmonary hypertension
JPWO2020198051A5 (https=)
Vecellio et al. Deposition in three nasal cast models with a new concept of nasal administration (Retronose) vs nasal spray
Hoppentocht et al. Design and development of a disposable high dose dry powder inhaler for aminoglycosides